RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Clinical trial NCT06063018 · RECRUITING
Trial details
- NCT number
- NCT06063018
- Sponsor
- Peking Union Medical College Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-16
- Primary completion
- 2025-08-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.